

## Supplementary Materials

### The Landscape of *BRCA* Mutations Among Egyptian Women with Breast Cancer

Hamdy A. Azim<sup>1,2#</sup>, Samah A. Loutfy<sup>3,4#</sup>, Hatem A. Azim Jr<sup>2</sup>, Nermin S. Kamal<sup>2</sup>, Nasra F. Abdel Fattah<sup>3</sup>, Mostafa H. Elberry<sup>3</sup>,  
Mohamed R. Abdelaziz<sup>5</sup>, Marwa Abdelsalam<sup>2</sup>, Madonna Aziz<sup>6</sup>, Kyrillus S. Shohdy<sup>1,7</sup>, Loay Kassem<sup>1,2\*</sup>

<sup>1</sup>Clinical Oncology Department, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt

<sup>2</sup>Medical Oncology Unit, Cairo Oncology Center, Cairo, Egypt

<sup>3</sup>Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Egypt

<sup>4</sup>Nanotechnology Research Center, BUE, Cairo, Egypt

<sup>5</sup>Oncology Medical Manager, Pfizer. Egypt

<sup>6</sup>Clinical Research Unit, Cairo Oncology Center, Cairo, Egypt

<sup>7</sup>Division of Cancer Sciences, The University of Manchester, Manchester, UK

#Authors contributed equally

#### \*Corresponding author

Loay Kassem.

**Affiliation:** Clinical Oncology Department, Kasr Alainy School of Medicine, Cairo University, Egypt.

**Email:** [loay.kassem@cairocure.com](mailto:loay.kassem@cairocure.com);

**Phone:** +201003022907.

**ORCID:** 0000-0001-6559-5867.

Table S1: Characteristics of individual patients with BRCA1 deleterious variants and VUS

BRCA 1											
ID	Variant	Deleterious	Age	Family history of BC	ER	PR	HER2	Ki67%	TNBC	Stage	Grade
20151027	c.3008_3009delTT (p.Phe1003*)	Yes	21	NA	Negative	Negative	Negative	90	Yes	NA	3
20040193	c.5095C>T (p.Arg1699Trp)	Yes	31	No	Positive	Positive	Negative	NA	No	NA	3
20170720	c.5266dupC (5382insC)	Yes	37	No	Positive	Positive	Negative	50	No	1	3
20200410	c.5363delG	Yes	36	Yes	Positive	Negative	Negative	70	No	2	3
20040010	c.83_84delTG, p.Leu28fs	Yes	27	No	Positive	Positive	Negative	NA	No	NA	3
NA	NM_007294.4, c.5444G>A, p.(W1815*)	Yes	33	No	Negative	Negative	Negative	30	Yes	NA	2
NA	NM_007300.3:c.5093_5096del	Yes	35	Yes	Negative	Negative	Negative	80	Yes	2	3
20200410	c.1648A>C, c.1456T>C, c.536A>G,	VUS	36	Yes	Positive	Negative	Negative	70	No	2	3

20171300	c.3526G>A, p.(Val1176Ile)	VUS	40	Yes	Positive	Positive	Negative	3	No	1	2
20161038	Exon 10 (1591T)	VUS	50	NA	Positive	Positive	Negative	10	No	4	2
20140825	c.4308T>C	VUS	36	Yes	Negative	Negative	Negative	10	Yes	NA	3
20181480	c.3737C>A, p.Thr1246Asn (T1246N)	VUS	41	Yes	Positive	Positive	Negative	4	No	2	2
20090882	c.4776C>G, p.Asn1592Lys	VUS	51	Yes	Positive	Positive	Negative	NA	No	NA	3
20131406	c.5332+7G>A	VUS	27	Yes	Positive	Positive	Negative	8	No	1	2

Table S2: Characteristics of individual patients with BRCA2 deleterious variants and VUS

BRCA 2											
ID	Variant	Deleterious	Age	Family history of BC	ER	PR	HER2	Ki67%	TNBC	Stage	Grade
20170720	exon 9 (frame shift 999 del) - Exon 11 F	Yes	37	No	Positive	Positive	Negative	50	No	1	3
NA	NM_000059.3, c.5722_5723del, p.(L1908Rfs*2)	Yes	49	No	Positive	Positive	Negative	NA	No	NA	2
20210396	c.4284dup	Yes	34	No	Positive	Positive	Negative	35	No	NA	3
20130514	chr13:32912530delT c.4038delT (p.Val1347PhefsTer27)	Yes	33	Yes	Positive	Positive	Negative	70	No	NA	2
20190919	c.4478_4481del (p.Glu1493fs)	Yes	32	Yes	Positive	Positive	Negative	18	No	3	2
20200797	c.6771C>T (p.Pro2257Pro)	VUS	51	Yes	Positive	Negative	Positive	15	No	4	2

20161334	c.9206G>T, p.(Cys3069Phe)	VUS	61	Yes	Positive	Positive	Positive	NA	No	4	2
20010535	c.1607C>A, p.(Ser536Tyr)	VUS	42	NA	Negative	Negative	Negative	NA	Yes	1	2
20210358	c.692G>C, p.(Ser231Thr)	VUS	66	Yes	Positive	Positive	Negative	5	No	NA	2
20170056	c.6513G>T, p.V2171V, c.1011C>T, p. N337N	VUS	38	NA	Positive	Positive	Negative	12	No	2	2
20131406	c.571G>T, p.Asp191Tyr (D191Y)	VUS	27	Yes	Positive	Positive	Negative	8	No	1	2